2 results
Approved WMOCompleted
To evaluate the feasibility of 89Zr-bevacizumab-PET imaging as predictive biomarker before and during treatment with everolimus in patients with neuroendocrine tumors.
Approved WMOPending
To evaluate the clinical utility of the NaPi2b (67) Assay for use in the detection of NaPi2b in formalin-fixed, paraffin-embedded (FFPE) serous ovarian carcinoma tissue to determine patient eligibility for treatment with XMT-1536.